|
 |
| ORIGINAL ARTICLE |
|
| Year : 2020 | Volume
: 24
| Issue : 5 | Page : 409-413 |
|
|
Soluble CD163 as a biomarker of periodontal disease – A biochemical study using enzyme-linked immunosorbent assay
Karthikeyan S.S Sai Karthikeyan, RG Shiva Manjunath, Geetika Kumar, Bharti Chaudhary
Department of Periodontics, Institute of Dental Sciences, Bareilly International University, Bareilly, Uttar Pradesh, India
| Date of Submission | 15-Feb-2020 |
| Date of Decision | 08-Apr-2020 |
| Date of Acceptance | 16-Apr-2020 |
| Date of Web Publication | 01-Sep-2020 |
Correspondence Address:
Dr. R G Shiva Manjunath
Department of Periodontics, Institute of Dental Sciences, Bareilly International University, Bareilly - 243 006, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jisp.jisp_97_20
 Abstract | | |
Background: The aim of the study was to evaluate the levels of soluble CD163 (sCD163) in gingival crevicular fluid (GCF) and blood serum of individuals having periodontitis, gingivitis, and healthy periodontium. Further, the role of sCD163 as a biomarker of periodontal disease was also assessed. Materials and Methods: A minimum of 5-μl GCF and 10 ml of venous blood was collected using a micropipette and 10-ml syringe, respectively, from the study population which was divided into three groups as healthy (Group I, n = 10), gingivitis (Group II, n = 10), and periodontitis (Group III, n = 10). sCD163 samples were assessed using a commercially available sCD163 enzyme-linked immunosorbent assay kit. Clinical parameters such as oral hygiene index simplified, gingival index (GI), percentage of sites with bleeding on probing, probing depth, and clinical attachment loss were recorded. Results: The mean serum sCD13 levels were 743.45 ± 51.17 ng/ml, 563.25 ± 103.74 ng/ml, and 431.0 ± 31.08 ng/ml when compared to the mean GCF sCD163 levels which were 59.81 ± 7.61 ng/ml, 38.93 ± 12.42 ng/ml, and 30.49 ± 12.60 ng/ml for periodontitis, gingivitis, and healthy individuals, respectively. The sCD163 levels were higher in patients with periodontitis when compared to the periodontally healthy individuals. Conclusion: Within the limitations of the present study, it can be concluded that sCD163 levels can be used as a diagnostic marker of disease as its levels are remarkably increased in GCFs of patients having periodontitis.
Keywords: Enzyme-linked immunosorbent assay, gingival crevicular fluid, macrophages, periodontal diseases, serum
How to cite this article:
Sai Karthikeyan KS, Shiva Manjunath R G, Kumar G, Chaudhary B. Soluble CD163 as a biomarker of periodontal disease – A biochemical study using enzyme-linked immunosorbent assay. J Indian Soc Periodontol 2020;24:409-13 |
How to cite this URL:
Sai Karthikeyan KS, Shiva Manjunath R G, Kumar G, Chaudhary B. Soluble CD163 as a biomarker of periodontal disease – A biochemical study using enzyme-linked immunosorbent assay. J Indian Soc Periodontol [serial online] 2020 [cited 2022 Aug 8];24:409-13. Available from: https://www.jisponline.com/text.asp?2020/24/5/409/294108 |
| Introduction | |  |
Periodontitis is a chronic inflammatory condition of the periodontium that affects the connective tissue attachment and alveolar bone around the teeth.[1] It is characterized by microbially associated, host-mediated inflammation that results in loss of periodontal attachment. The net result is apical migration of the junctional epithelium and pathological deepening of the gingival sulcus, allowing the pathogenic bacteria to enter the host tissue.[2] All the key pathways of the pathophysiology are mediated by the immune system of the host. The PMNs constitute to the innate immunity, whereas the lymphocytes constitute the adaptive immunity.[3] The bridging between the innate and the adaptive immunities is played by the mononuclear cells, i.e., the monocyte/macrophage lineage of cells.[4]
Macrophages release an array of cytokines that activate T cytotoxic lymphocytes for pathogen killing and B-lymphocytes to secrete immunoglobulins.[5] The categorization or polarization of macrophages into the M1 (classical activation) and M2 (alternative activation) subtypes is a simplified operation-based classification depending on the specific signals from the microenvironment, location, and disease state.[6],[7],[8] CD163 is a glycosylated membrane protein that is expressed almost exclusively on M2 macrophages and to a lesser extent on M1 macrophages.[9],[10],[11] CD163 belongs to the scavenger receptor cysteine-rich (SRCR) family and comprises nine extracellular SRCR protein domains that are linked to a short transmembrane segment and a short cytoplasmic tail. The locus for synthesis of CD163 lies on chromosome 12p13 and is composed of 17 exons.[12]
Soluble CD163 (sCD163) is shed in large quantities as a response to increased inflammatory condition to reduce the damage caused to the host by the host-derived enzymes and in reduced quantities during health by the anti-inflammatory cytokines to maintain tissue homeostasis.[12],[13] Several studies have proven the increased presence of sCD163 in other body fluids during chronic inflammatory conditions such as rheumatoid arthritis, atherosclerosis, and metabolic syndrome-related conditions such as diabetes, obesity, and chronic kidney disease.[13],[14],[15] Although increased levels of sCD163 were found in serum and saliva of periodontitis patients,[15] the exact variation of the same in the gingival crevicular fluid (GCF) of periodontal health and disease is not clear till date. sCD163 is one such marker of macrophages that can be measured consistently even in smaller amounts with low intra-individual variability. Due to high specificity of sCD163 on monocytic-macrophage lineage and well-documented evidences of its (sCD163) presence in other chronic inflammatory conditions, sCD163 was chosen to be assessed in this present study. Hence, the aim of this study was to assess the sCD163 levels in GCF and serum from periodontal health to disease.
| Materials and Methods | | |
Study population and clinical examination
The present cross-sectional study was conducted by selecting 30 individuals from the outpatient department of periodontology and implantology. The study sample included 17 males and 13 females, with age group ranging from 22 to 42 years. The study protocol was approved by the institutional ethics committee and was conducted in accordance with the Helsinki Declaration of 1975, as revised in 2013. Return informed consent was obtained from the individuals, and then, they were included in the study. The individuals were included in the study if they showed clinical signs of health and disease [16],[17] and minimum age of at least 21 years and not extending more than 65 years and had at least 20 teeth. Individuals who underwent periodontal therapy in the past 3 months, those taking any sort of medication that could alter the course of disease or influence inflammatory state, those suffering from any sort of systemic disease that could contribute to disease occurrence and progression, pregnant and lactating females, current smokers, and alcoholics were excluded from the study. The study was conducted from June 2019 to September 2019, and the individuals were stratified into healthy, gingivitis, and periodontitis groups, respectively, as Groups I, II, and III. Periodontal health was considered when an individual did not show any signs of bleeding on probing (BoP) and not having clinical attachment loss (CAL). Gingivitis was defined when an individual showed BoP and inflammation without any periodontal pocket or CAL. An individual was considered to be having periodontitis if at least two nonadjacent teeth showed interproximal CAL of ≥3 mm with radiographic evidence of bone loss. Oral hygiene status and inflammatory status were recorded using oral hygiene index simplified (OHIS)[18] and gingival index (GI)[19] at the time of clinical examination. BoP was recorded as a dichotomous index [15] (present or absent) and was expressed in percentage of bleeding. To maintain standardization and intra-examiner reproducibility probing depth (PD), CAL was recorded by a single examiner using a UNC-15 probe.
Gingival crevicular fluid collection
All the clinical parameters were recorded on the 1st day, whereas the sample collection was done on the subsequent day. This was done to prevent bias that would have been caused due to stimulated secretion of GCF due to mechanical handling of tissues while recording clinical measurements, and the sample collection was done according to the procedure described by Pradeep et al.[20] Briefly, the site chosen for sample collection was gently dried and isolated using cotton rolls to prevent saliva contamination. Supragingival plaque was removed, and a 10-μl micropipette (Nichipet EX-Plus II pipette, MERCK, © 2020 Merck KGaA, Darmstadt, Germany) was introduced into the gingival sulcus for collecting at least 5-μl GCF. One site per individual was selected for collection of GCF in gingivitis and periodontitis patients, whereas at least 3 sites per individual were used in the healthy group to ensure adequate collection of GCF. Samples contaminated with blood or saliva were discarded, and new sites were chosen for sample collection. Sites having the highest amount of inflammation and sites having the highest CAL were chosen for the collection of GCF sample in gingivitis and periodontitis patients, respectively. Air-protected plastic vials that were maintained at −70°C were used for storing GCF samples till enzyme-linked immunosorbent assay (ELISA) was performed.
Serum collection
Required quantity (10 ml) of blood was drawn using a 20G syringe from the antecubital vein. The collected blood sample was allowed to clot and was subjected to low-speed centrifugation at 2800 rpm for 5 min. Due to centrifugation, the serum got separated from the blood. The separated serum was stored separetely in air protected plastic vials at-70 C.
Soluble CD163 analysis
sCD163 levels in both GCF and serum were analyzed using a commercially available aCD163 ELISA kit (Human CD163 ELISA Kit, MERCK, © 2020 Merck KGaA, Darmstadt, Germany). The sandwich method was performed according to the procedural instructions provided along with the kit. Briefly, all the samples and the reagents of the kit were brought to room temperature (18°C–25°C) and were diluted to required proportions. Five hundred microliters of standard and sample solution (GCF and serum) was coated to the wells of ELISA kit and allowed to incubate for 2.5 h at room temperature. After incubation, the wells were washed 4 times with 300-μl phosphate-buffered saline. Later, 500 μl of detection antibody was coated on to the wells and were allowed to incubate for 1 h at room temperature after which the wells were again washed 4 times with 300-μl phosphate-buffered saline. One hundred microliters of streptavidin solution was added to all the wells, incubated for 45 min at room temperature, and was again washed 4 times with 300-μl phosphate-buffered saline. One hundred microliters of tetramethylbenzidine was added which imparts color to the wells and was incubated for 30 min at room temperature after which 50 μl of stop solution was added to stop the coloring reaction. Then, the ELISA plate was fed into an optical plate reader, and the absorbance of standard was read at 450 nm. The absorbance of the samples was compared with the absorbance of standard, and the concentrations of sCD163 were charted accordingly.
Statistical analysis
The data were entered into a Microsoft Excel spreadsheet and imported to the SPSS software (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.) for statistical analysis. The result was presented in the form of mean and standard deviation. One-way ANOVA test was performed for intergroup comparison of sCD163 levels and clinical parameters. Student's unpaired t-test was used for pairwise comparison of OHIS and GI, whereas Chi-square test was used to find association in bleeding index in between different groups. P < 0.05 was considered statistically significant.
| Results | | |
[Table 1] shows the demographic data of the study population in mean ± standard deviation. Unpaired t-test for intergroup comparison for OHIS showed a significant difference (P < 0.001) in all the three groups. The mean OHIS score in periodontitis (4.80 ± 0.68) was higher than that of the gingivitis (2.38 ± 0.58) and healthy (0.87 ± 0.41) groups, as shown in the table. The inflammatory index scores were also significant among the three groups. The mean scores for inflammatory index in the periodontitis group (2.69 ± 0.29) were higher than those in the gingivitis (1.54 ± 0.20) and healthy groups (0.57 ± 0.42). | Table 1: Descriptive data (mean±standard deviation) of the study population and the soluble CD163 levels with one-way ANOVA test
Click here to view |
One-way ANOVA of sCD163 levels [Table 1] showed statistically significant differences among all the three groups. The mean serum sCD163 levels in the periodontitis group (743.45 ± 51.17 ng/ml) were more than the mean serum sCD163 levels in the gingivitis group (563.25 ± 103.74 ng/ml) and healthy group (431.03 ± 31.08 ng/ml). Similarly, the mean GCF sCD163 levels in the periodontitis group (59.81 ± 7.61 ng/ml) were more when compared to the GCF samples in the gingivitis group (38.93 ± 12.42 ng/ml) and healthy group (30.49 ± 12.60 ng/ml) which were almost near to the lower sensitivity range of the ELISA kit (30 ng/ml).
Chi-square test [Table 2] for bleeding index was done for intergroup comparison as the bleeding index was taken as dichotomous variables, i.e., bleeding present or absent. The intergroup comparison for bleeding index showed a significant difference (<0.001) among all the three groups. | Table 2: Percentage of bleeding in the study population with Chi-square test
Click here to view |
Multiple comparisons were done using unpaired t-test [Table 3], which was performed to confirm which group or groups differed statistically at the 5% level of significance. All the comparisons showed statistically significant differences for both GCF and serum sCD163 samples. | Table 3: Pairwise comparison of soluble CD163 levels with Student's unpaired t-test
Click here to view |
| Discussion | | |
sCD163 is a hemoglobin-scavenging protein which is increased during inflammatory conditions to counteract the destruction caused by classically activated macrophages (M1 macrophages). Several studies have been performed in which sCD163 was observed in various other body fluids,[21],[22],[23] but there is little evidence demonstrating the presence of sCD163 in GCF.
The results of the present study showed that the patients with periodontitis showed higher levels of sCD163 levels both in serum and GCF when compared to healthier individuals. The results also correlated with the increase in PDs along with the increase in GCF levels of sCD163 levels. This study reported a mean serum sCD163 level of 743.45 ± 51.17 ng/ml in periodontitis patients, 563.25 ± 103.74 ng/ml in gingivitis patients, and 431.03 ± 31.08 ng/ml in healthy individuals. A study done by Detzen et al.[15] in saliva and serum of periodontitis patients demonstrated elevated serum levels of sCD163 (720.0 ± 330.6 ng/ml) which are comparable to the serum sCD163 levels of the present study. The subdue decrease in the GCF sCD163 levels from the serum sCD163 levels may be due to the molecular weight of sCD163 (130 kDa) which is higher when compared to the most commonly found proteins in GCF which are <79 kDa.[24] The tissue barriers and cellular transport of CD163 are some other factors which play a role in expression of sCD163 in GCF.[25] The two-way interrelationship between periodontal disease and systemic health might be the reason for increase in the serum sCD163 levels even in the systemically healthy individuals.[26],[27]
Free hemoglobin that is released into the blood forms hemoglobin/haptoglobin complexes which is one of the strong causes of oxidative stress and pro-inflammatory changes that occur in the tissues.[12],[28],[29] The best-known function of CD163 is the clearance of these hemoglobin/haptoglobin complexes in its cell-free form and participate as an anti-inflammatory soluble factor, exhibiting cytokine-driven functions. Furthermore, transforming growth factor (TGF)-beta has a role in downregulating CD163 secretion.[30] It downregulates the expression of CD163 secretion. However, due to biologic synergism of interleukin-6 (IL-6) and macrophage colony-stimulating factor (M-CSF) which are abundantly found in periodontal inflammation, the downregulation caused by TGF-beta might be overtaken by the upregulation caused by IL-6 and M-CSF.[31] In vitro studies of cultured monocytes/macrophages have shown that the shedding of sCD163 can be induced by toll-like receptor (TLR) activation by lipopolysaccharide (LPS) or phorbol 12-myristate 13-acetate, crosslinking of the Fcγ receptor, oxidative stress, and thrombin.[10],[11],[32],[33],[34] Notably, these are the mechanisms that would be occurring in periodontal disease that leads to destruction of the periodontium. However, the long-term effects of TLR stimulation by LPS on sCD163 expression requires further research. Further, sCD163 has been proposed to mediate innate immune defense by sequestering hemoglobin-bound iron that would otherwise be available to pathogens as a nutrient source. sCD163 inhibits lymphocyte proliferation and activation, but the receptor to which it binds on lymphocytes has not been identified.[35],[36],[37],[38]
As for our knowledge, this study is the first of its kind which was performed using both GCF samples and serum samples for assessing sCD163 levels. The strength of this study lies in the fact that GCF is a definitive diagnostic marker as it can detect subclinical alterations in cell metabolism, immune cell recruitment, pathophysiology of connective tissue, and alveolar bone remodeling.[39] This study also opens vistas for new research such as the effect of anti-inflammatory cytokines and antigen-presenting cells on the sCD163 secretion, i.e., there is evidence for increased expression of CD163 due to IL-10 but not vice versa. Hence, as IL-10 is also present increasing CD163 expression, there might be an increase in the number of IL-10-producing dendritic cells. Limitations of the present study include the small sample size that was taken into the study. The total number of colony-forming units of Porphyromonas gingivalis could have been performed as the lipopolysaccharide of P. gingivalis has the potential to stimulate the release of sCD163 from macrophages. Since sCD163 is a hemoglobin scavenger receptor, the levels of free hemoglobin could have been assessed that would have helped in adding strength to the study. The assessment of sCD163 is a noninvasive method that can be used to observe the periodontal condition of an individual. Future studies and scientific research directed toward developing a chairside test for sCD163 in quantifying the health and disease states during the epidemiologic studies will help us in arriving at an early diagnosis and formulating a treatment plan accordingly.
| Conclusion | | |
This is the first study to use GCF for assessing the levels of sCD163 in health and disease. The GCF and serum levels of sCD163 markers increased from health to disease. Within the limitations of the present study, it can be concluded that sCD163 levels can be used as a diagnostic marker of disease as its levels are remarkably increased in GCFs of patients having periodontitis. Long-term follow-up and therapeutic studies with increased sample size are required to confirm the role of sCD163 in periodontitis. Pre operative, post operative and follow up interval levels of sCD163 could also be measured for arriving at a stronger evidences of considering sCD163 as a marker for periodontal disease.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | | |
| 1. | Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Periodontol 2018;89 Suppl 1:S159-S172.  |
| 2. | Page RC, Kornman KS. The pathogenesis of human periodontitis: An introduction. Periodontol 2000 1997;14:9-11. |
| 3. | Dixon DR, Bainbridge BW, Darveau RP. Modulation of the innate immune response within the periodontium. Periodontol 2000 2004;35:53-74. |
| 4. | Chehimi J, Trinchieri G. Interleukin-12: A bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol 1994;14:149-61. |
| 5. | Arango Duque G, Descoteaux A. Macrophage cytokines: Involvement in immunity and infectious diseases. Front Immunol 2014;5:491. |
| 6. | Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol 2014;5:614. |
| 7. | Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958-69. |
| 8. | Konermann A, Stabenow D, Knolle PA, Held SA, Deschner J, Jäger A. Regulatory role of periodontal ligament fibroblasts for innate immune cell function and differentiation. Innate Immun 2012;18:745-52. |
| 9. | Kowal K, Silver R, Sławińska E, Bielecki M, Chyczewski L, Kowal-Bielecka O. CD163 and its role in inflammation. Folia Histochem Cytobiol 2011;49:365-74. |
| 10. | Ambarus CA, Krausz S, van Eijk M, Hamann J, Radstake TR, Reedquist KA, et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods 2012;375:196-206. |
| 11. | Lehtonen A, Ahlfors H, Veckman V, Miettinen M, Lahesmaa R, Julkunen I. Gene expression profiling during differentiation of human monocytes to macrophages or dendritic cells. J Leukoc Biol 2007;82:710-20. |
| 12. | Moestrup SK, Møller HJ. CD163: A regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 2004;36:347-54. |
| 13. | Møller HJ. Soluble CD163. Scand J Clin Lab Invest 2012;72:1-13. |
| 14. | Davis BH, Zarev PV. Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom 2005;63:16-22. |
| 15. | Detzen L, Chen SCY, Cheng B, Papapanou PN, Lalla E. Increased levels of soluble CD163 in periodontitis patients. J Clin Periodontol 2017;44:585-90. |
| 16. | Lang NP, Bartold PM. Periodontal health. J Periodontol. 2018;89 Suppl 1:S9-16. |
| 17. | Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Clin Periodontol 2018;45 Suppl 20:S149-S161. |
| 18. | Greene JC, Vermillion JR. The simplified oral hygiene index. J Am Dent Assoc 1964;68:7-13. |
| 19. | Shaw L, Murray JJ. Diagnostic reproducibility of periodontal indices. J Periodontal Res 1977;12:141-7. |
| 20. | Pradeep AR, Raghavendra NM, Prasad MV, Kathariya R, Patel SP, Sharma A. Gingival crevicular fluid and serum visfatin concentration: Their relationship in periodontal health and disease. J Periodontol 2011;82:1314-9. |
| 21. | Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, et al. Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol 2002;130:156-61. |
| 22. | Zhou D, Wang Y, Chen LU, Zhang W, Luan J. Soluble CD163: A novel biomarker with diagnostic and therapeutic implications in autoimmune diseases. J Rheumatol 2016;43:830. |
| 23. | Thomas AJ, Ogilvy CS, Griessenauer CJ, Hanafy KA. Macrophage CD163 expression in cerebrospinal fluid: Association with subarachnoid hemorrhage outcome. J Neurosurg 2018;131:47-53. |
| 24. | Curtis MA, Sterne JA, Price SJ, Griffiths GS, Coulthurst SK, Wilton JM, et al. The protein composition of gingival crevicular fluid sampled from male adolescents with no destructive periodontitis: Baseline data of a longitudinal study. J Periodontal Res 1990;25:6-16. |
| 25. | Barros SP, Williams R, Offenbacher S, Morelli T. Gingival crevicular fluid as a source of biomarkers for periodontitis. Periodontol 2000 2016;70:53-64. |
| 26. | Iacopino AM, Cutler CW. Pathophysiological relationships between periodontitis and systemic disease: Recent concepts involving serum lipids. J Periodontol 2000;71:1375-84. |
| 27. | Arigbede AO, Babatope BO, Bamidele MK. Periodontitis and systemic diseases: A literature review. J Indian Soc Periodontol 2012;16:487-91. [ PUBMED] [Full text] |
| 28. | Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: Antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 2004;94:119-26. |
| 29. | Zwadlo G, Voegeli R, Schulze Osthoff K, Sorg C. A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol 1987;55:295-304. |
| 30. | Sulahian TH, Pioli PA, Wardwell K, Guyre PM. Cross-linking of FcgammaR triggers shedding of the hemoglobin-haptoglobin scavenger receptor CD163. J Leukoc Biol 2004;76:271-7. |
| 31. | Yongchaitrakul T, Lertsirirangson K, Pavasant P. Human periodontal ligament cells secrete macrophage colony-stimulating factor in response to tumor necrosis factor-alpha in vitro. J Periodontol 2006;77:955-62. |
| 32. | Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the haemoglobin scavenger receptor. Nature 2001;409:198-201. |
| 33. | Chung S, Kim JE, Park S, Han KS, Kim HK. Neutrophil and monocyte activation markers have prognostic impact in disseminated intravascular coagulation: In vitro effect of thrombin on monocyte CD163 shedding. Thromb Res 2011;127:450-6. |
| 34. | Weaver LK, Hintz-Goldstein KA, Pioli PA, Wardwell K, Qureshi N, Vogel SN, et al. Pivotal advance: Activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol 2006;80:26-35. |
| 35. | Högger P, Sorg C. Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation. Biochem Biophys Res Commun 2001;288:841-3. |
| 36. | Frings W, Dreier J, Sorg C. Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester-activated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett 2002;526:93-6. |
| 37. | Timmermann M, Buck F, Sorg C, Högger P. Interaction of soluble CD163 with activated T lymphocytes involves its association with non-muscle myosin heavy chain type A. Immunol Cell Biol 2004;82:479-87. |
| 38. | Timmermann M, Högger P. Oxidative stress and 8-iso-prostaglandin F(2alpha) induce ectodomain shedding of CD163 and release of tumor necrosis factor-alpha from human monocytes. Free Radic Biol Med 2005;39:98-107. |
| 39. | Loos BG, Tjoa S. Host-derived diagnostic markers for periodontitis: Do they exist in gingival crevice fluid? Periodontol 2000 2005;39:53-72. |
[Table 1], [Table 2], [Table 3]
|
| 
